ArticleFrontiers in cardiovascular medicine2026
Right-heart reverse remodeling and heart failure symptom outcomes after catheter ablation in patients with persistent atrial fibrillation, heart failure, and functional tricuspid regurgitation.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Persistent atrial fibrillation (AF) and heart failure (HF) may promote right-heart remodeling and functional tricuspid regurgitation (FTR). Evidence regarding right-heart changes after first AF ablation in patients with persistent AF, HF, and FTR remains limited. This study assessed 12-month right-heart reverse remodeling and its associations with HF symptoms and exploratory clinical events. Methods: This retrospective single-center cohort included 210 patients with persistent AF, HF with reduced, mildly reduced, or preserved ejection fraction, and at least mild FTR undergoing first catheter ablation. Transthoracic echocardiography (TTE) was performed at baseline and 12 months. Significant right-heart reverse remodeling was defined as a ≥10% reduction in right atrial volume index (RAVI) plus a ≥10% reduction in right ventricular (RV) basal diameter or tricuspid annular diameter, without worsening tricuspid regurgitation (TR) or RV function. Logistic regression, rhythm/loading and threshold sensitivity analyses, and 12-month landmark Cox models were used. Results: At 12 months, RAVI changed by -19.3% [interquartile range (IQR), -30.5% to -6.8%]; 93 patients (44.3%) achieved remodeling, 57.1% had TR improvement, and 61.0% had HF symptom improvement. Sinus rhythm during echocardiography increased from 16.7% to 78.6%, while heart failure guideline-directed medical therapy (HF-GDMT) and sodium-glucose cotransporter 2 (SGLT2)-inhibitor use increased. Same-rhythm and rhythm/loading-adjusted analyses showed directionally consistent but attenuated improvements in right-heart dimensions, pulmonary artery systolic pressure, and TR grade. Long-standing persistent AF, higher baseline RAVI, higher pulmonary artery systolic pressure, and arrhythmia recurrence within 12 months were associated with lower odds of remodeling, whereas higher estimated glomerular filtration rate (eGFR) and HF-GDMT were associated with higher odds. After the 12-month landmark, arrhythmia recurrence and HF rehospitalization were less frequent with remodeling. Conclusions: In this single-arm retrospective cohort, right-heart reverse remodeling observed after first AF ablation was associated with TR improvement, HF symptom improvement, and lower exploratory post-landmark event rates. The single-arm design, rhythm/loading changes, HF-GDMT intensification, and short post-landmark follow-up support associative and hypothesis-generating interpretation; causal attribution requires prospective controlled studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.